GlaxoSmithKline launches low dose birth control pill

GlaxoSmithKline Pharmaceuticals Limited has launched a low dose pill (LDP) "� Elogen "� for birth control. A low dose pill typically has less than 50 micrograms (mcg) of estrogen.

It is a prescription drug and is, therefore, not available over-the-counter. Since Elogen has less estrogen content (20 mcg), it claims to reduce the side effects that are usually associated with the conventional birth control pills.

"In India, birth control pills are not widely used because there are myths associated with it. These are related to cancer, infertility, miscarriage and obesity. That is why the usage of pills is just two per cent in the country," D Pushpalatha, consulting obstetrician and gynaecologist, said here on Thursday.

"Elogen, however, is reliable and provides benefits in the form of excellent cycle control and protection from ovarian and endometrial cancer. The side effects related to nausea, vomiting and weight gain are also negligible in this regard," she added.

LDPs have been available in the Indian market since the last two years. At present, there are around 16 companies that are in the oral contraceptive (prescription) market worth Rs 80 crore. Elogen is priced at Rs 90 for 21 pills.